Omeprazole is a proton pump inhibitor indicated for GERD, erosive esophagitis, duodenal and gastric ulcers and H. pylori eradication. We supply it to US manufacturers of delayed-release capsules and delayed-release tablets (OTC).
Data from PubChem (CID 4594) and FDA’s substance registry
CAS number
73590-58-6
Molecular formula
C17H19N3O3S
Molecular weight
345.4g/mol
FDA UNII
IUPAC name
6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole
InChIKey
SUBDBMMJDZJVOS-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline powder that melts with decomposition at about 155 °C.
- Solubility
- Very slightly soluble in water. Freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Unstable in acid and sensitive to heat, light and moisture, so agree on temperature-controlled shipping before the first order. Enteric-coated omeprazole pellets are a different product from the API.
On the US market
- Reference product
- PrilosecNDA 019810
- Approved ANDAs
- 17 with a marketed product
- Approved forms and strengths
- Delayed-release capsule (pellets) 10 mg, 20 mg, 40 mg
- Delayed-release tablet 20 mg
- Delayed-release orally disintegrating tablet 20 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com